Back
Science

AHA/ACC Release First Comprehensive Pulmonary Embolism Guidelines Amidst New Outcome Research

Generated on: Last updated: 2 sources
View source

Landmark 2026 Guidelines Reshape Pulmonary Embolism Evaluation and Management

The American Heart Association (AHA) and American College of Cardiology (ACC) released their first comprehensive clinical guidelines for pulmonary embolism (PE) in 2026. This landmark release marks a notable change in the condition's evaluation and management. Concurrently, new research utilizing global and U.S. data provided fresh insights into short-term patient outcomes, hospitalization trends, and mortality rates, indicating persistent challenges in PE care despite advancements.

The new 2026 AHA/ACC guidelines are set to transform PE care, alongside new research highlighting ongoing challenges in patient outcomes.

Overview of Pulmonary Embolism

Pulmonary embolism is a serious condition caused by blood clots blocking arteries in the lungs, contributing to health burdens globally and an estimated 400,000 annual hospitalizations in the United States. Care for PE increasingly involves cardiovascular specialists, utilizing advanced diagnostic and management tools such as echocardiography, biomarkers (troponin, NT-proBNP), and catheter-based interventions.

The Journal of the American College of Cardiology (JACC) dedicated its April issue to PE, highlighting these new guidelines and related research. Contributors to both the guidelines and the JACC issue included experts from Mass General Brigham, such as Dr. Gregory Piazza, Dr. Rachel Rosovsky, the late Dr. Ido Weinberg, and Dr. Behnood Bikdeli.

2026 AHA/ACC Guidelines for Acute Pulmonary Embolism

The 2026 guidelines represent the first formal AHA/ACC guidelines specifically addressing PE, offering a comprehensive framework for patient care.

Key aspects of the new guidelines include:

  • Clinical Categories: Introduction of five new clinical categories designed to classify the wide range of PE severity, from asymptomatic cases to cardiac arrest. This classification aims to improve risk stratification and tailored management.
  • Post-PE Syndrome: Emphasis on crucial follow-up care between three and six months post-event to assess for post-PE syndrome. This syndrome can manifest as persistent shortness of breath, fatigue, reduced exercise tolerance, difficulty resuming daily activities, and significant psychological impacts.
  • Ongoing Management: Follow-up also includes reassessing the risks and benefits of ongoing blood thinner therapy and providing clear guidance on safely resuming daily activities.

Global Study on 90-Day Outcomes After Pulmonary Embolism

A significant global study, led by Dr. Behnood Bikdeli, examined trends in short-term outcomes for PE patients. Utilizing data from the RIETE international registry, which included over 31,000 adults treated for PE between 2016 and 2024, the study evaluated rates of death, recurrent blood clots, and serious bleeding within 90 days of a PE event.

The findings revealed:

  • Mortality: Approximately 6% to 7% of patients died within 90 days. This rate remained largely unchanged over the study period, despite advancements in imaging and medications.
  • Bleeding: Rates of serious bleeding related to treatment also showed no significant change.
  • Recurrence: A modest decline in recurrent blood clots was observed, suggesting some improvement in preventing repeat events.

These findings indicate that PE remains a condition associated with substantial risks and highlight ongoing challenges in patient care.

U.S. Study on PE-Related Hospitalizations and Mortality

A separate study analyzed data from the U.S. National Inpatient Sample, focusing on 1.3 million adults hospitalized with PE as the primary diagnosis between 2016 and 2022.

Key observations from the U.S. data include:

  • Hospitalization Rates: Generally stable, with a notable increase observed during 2020 and 2021, coinciding with the COVID-19 pandemic.
  • Mortality: PE-attributable mortality, based on CDC data, showed a gradual increase over time but an unexpected decline in 2020. This suggests potential limitations in current surveillance tools, with ongoing efforts to improve data accuracy for epidemiological feature estimation.

The study highlights the persistent presence of PE in the United States and the ongoing need for continued improvements in prevention, risk stratification, and management strategies.

Conclusion

Pulmonary embolism is a frequently encountered diagnosis, identified as a common and potentially fatal condition. It is associated with significant demands on individuals and society, contributing to an estimated 50,000 deaths annually in the U.S. alone. While PE's prevalence and impact are well-documented, public awareness and the consistent application of updated clinical practices regarding optimal diagnosis, acute management, and follow-up care may still require improvement.

PE is a common, potentially fatal condition, impacting thousands annually. Improved public awareness and consistent application of updated clinical practices are crucial for better outcomes.